Association between triglyceride-glucose index and depression in middle-aged and older adults with hypertension: insights from the CHARLS study Authors: Haiyan Wei, Le Liang, Qingwen Xiao, Furong Guo, Heyin Yang Published: 2025 ABSTRACT Depression is a common comorbidity in hypertensive patients, but its metabolic predictors remain underexplored. This study investigates the association between the triglyceride-glucose (TyG) index and depression risk in hypertensive individuals aged ≥ 45 years. Using longitudinal data from the China Health and Retirement Longitudinal Study (CHARLS), we analyzed 3549 participants, categorizing TyG levels into quartiles and defining depression based on a score of ≥ 12 on the 10-item Center for Epidemiologic Studies Depression Scale. Logistic regression indicated that participants in the highest TyG quartile had a significantly higher risk of depression (odds ratio [OR]: 1.74, 95% confidence interval [CI] 1.21–2.51, P < 0.001). Restricted cubic spline analysis revealed a linear dose–response relationship. Additionally, receiver operating characteristic analysis showed that the TyG index was a more accurate predictor of depression risk compared to individual triglyceride and glucose measures. These findings suggest that elevated TyG levels are associated with an increased risk of depression in hypertensive middle-aged and older adults, highlighting its potential as a biomarker for identifying high-risk individuals.Supplementary InformationThe online version contains supplementary material available at 10.1038/s41598-025-28102-6. Introduction Depression is a globally prevalent mental health disorder that significantly impairs the quality of life of affected individuals, while also increasing the risk of comorbidities and mortality1. According to the World Health Organization, depression is projected to become the leading cause of disability worldwide by 20302. Depression is not only closely associated with psychological factors, but also with various physical health conditions, particularly cardiovascular diseases, neurological disorders, and metabolic diseases3,4. Among these, hypertension, one of the most common cardiovascular diseases, has been significantly linked with the development of depression. Research indicates that approximately 26.8% of hypertensive patients also suffer from depression5,6. In China, about 30–43% of adults aged 45 years and older experience depressive symptoms7, and those with comorbid depression are more likely to exhibit metabolic abnormalities and chronic diseases than their non-depressed peers8. This age group not only represents the core population of the nationally representative CHARLS cohort, but also marks a critical period when metabolic disturbances, hypertension, and psychological vulnerability tend to converge. These factors together justify the importance of focusing on middle-aged and older adults with hypertension when investigating the metabolic correlates of depression. Insulin resistance (IR), a hallmark feature of hypertension and various other diseases, has also been closely associated with the onset of depression. IR not only impairs the body’s response to insulin, but may also contribute to arterial stiffness and exacerbate hypertension through mechanisms such as hyperinsulinemia, endothelial dysfunction, oxidative stress, and inflammation9. Furthermore, IR has been shown to disrupt the balance of neurotransmitters in the brain, potentially initiating or intensifying depressive symptoms10–12. Although the insulin clamp and intravenous glucose tolerance test are considered the gold standards for assessing IR, their complexity and time-consuming nature limit their widespread use in clinical practice13. In recent years, the triglyceride-glucose (TyG) index, a simpler and cost-effective biomarker of IR, has gained significant attention in clinical research and has become an effective tool for early identification of IR14. Studies have found that higher TyG index values are associated with a greater likelihood of depressive symptoms in adults in the United States (US)15,16, and similar positive associations between TyG index and depression have been observed in Chinese adults as well17. Although a cross-sectional study has suggested a potential link between the TyG index and depression among hypertensive populations in the US, longitudinal studies exploring the relationship between the TyG index and the incidence of depression in hypertensive middle-aged and older adults in China remain scarce18. Therefore, this study aims to examine the relationship between the TyG index and the onset of depression in hypertensive individuals aged 45 and older in China, utilizing the China Health and Retirement Longitudinal Study (CHARLS) database, in order to address the existing gap in this area of research. Materials and methods Study population The CHARLS is a nationwide longitudinal survey designed to collect comprehensive health and socio-economic data from individuals aged 45 and older in China. To ensure the representativeness of the sample, a multi-phase probability sampling approach was employed during the initial data collection. Participants are re-evaluated every 2–3 years to monitor changes in their health conditions. As of now, five waves of follow-up have been completed. In each wave, trained interviewers conducted face-to-face interviews to gather sociodemographic and health-related information. For this longitudinal study, data from the 2011 and 2018 CHARLS waves were utilized, with the 2011 survey serving as the baseline. Initially, 7654 hypertensive participants were selected from the CHARLS database. Following the application of specific exclusion criteria, individuals were excluded if they: (1) were younger than 45 years of age (n = 175); (2) had missing data on triglyceride (TG) and fasting blood glucose (FBG) (n = 2392); (3) had a history of memory disorders or mental health conditions (n = 212); (4) had missing data on the 10-item Center for Epidemiologic Studies Depression Scale (CESD-10) or were lost to follow-up (n = 144); (5) had depression in 2011 (n = 1182). As a result, 3549 participants met the inclusion criteria and were included in the final analysis (Fig. 1).Fig. 1Study flowchart.CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CHARLS: China Health and Retirement Longitudinal Study; FBG: fasting blood glucose; TG: triglyceride. Study flowchart.CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CHARLS: China Health and Retirement Longitudinal Study; FBG: fasting blood glucose; TG: triglyceride. Ethical approval for the CHARLS study was granted by the Institutional Review Board of Peking University (IRB00001052-11,015). All participants provided informed consent through signed consent forms before participation. Measurement of depression and TyG Depression was assessed using the CESD-10, a widely recognized and validated tool commonly used in large-scale population studies to measure depressive19. The CESD-10 contains 10 questions, each scored from 0 to 3 based on how long the respondent experienced each symptom in the past week, resulting in a total score ranging from 0 to 30. It includes items such as “bothered by little things”, “felt depressed”, and “could not get going”. Higher scores reflect greater severity of depressive symptoms. A score of 12 or higher was considered indicative of depression20. For the measurement of metabolic parameters, TG and FBG levels were obtained using a standard enzymatic colorimetric method. The TyG index was then calculated as ln (fasting TG [mg/dL] × FBG [mg/dL] / 2)21,22. Participants were categorized into four groups according to the quartiles of their TyG index: Q1 (< 8.32), Q2 (≥ 8.32–8.73), Q3 (≥ 8.73–9.19), and Q4 (≥ 9.19). Data collection and definitions In this study, we grouped variables into several broad categories: sociodemographic characteristics (including age, gender, marital status, residence, and educational level), anthropometric measures (such as body mass index [BMI]), health behaviors (smoking and drinking), medical history, and laboratory parameters, which included total cholesterol (TC), TG, high-density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), FBG, and glycated hemoglobin (HbA1c). Smoking status was categorized into “Never or Former” and “Current” smokers, while drinking status was similarly classified as “Never or Former” and “Current” drinkers. Hypertension was identified through self-report, treatment for hypertension, or measured blood pressure values of ≥ 140 mmHg for systolic blood pressure (SBP) or ≥ 90 mmHg for diastolic blood pressure (DBP). Dyslipidemia was defined by self-reported physician diagnosis, current use of lipid-lowering medications, or any of the following criteria: TC ≥ 240 mg/dL, TG ≥ 150 mg/dL, HDL-C < 40 mg/dL, or LDL-C ≥ 160 mg/dL. These variables were included to describe the baseline characteristics of the study population, as presented in Table 1.Table 1Baseline characteristics of participants categorized by TyG quartiles.CharacteristicOverall (n = 3549)TyGQuartile 1 (n = 887)Quartile 2 (n = 887)Quartile 3 (n = 887)Quartile 4 (n = 888)P valueAge, mean ± SD, years61.1 ± 9.661.7 ± 10.261.7 ± 9.661.5 ± 9.759.5 ± 8.8 < 0.001Gender, n (%) < 0.001Female, n (%)1820 (51.3)367 (41.4)447 (50.4)529 (59.6)477 (53.7)Male, n (%)1729 (48.7)520 (58.6)440 (49.6)358 (40.4)411 (46.3)BMI, kg/m225.05 ± 12.5623.59 ± 11.5825.21 ± 13.7625.44 ± 13.8426.00 ± 14.010.036Married, n (%)3095 (87.2)759 (85.6)768 (86.6)759 (85.6)809 (91.1)0.001Residence, n (%) < 0.001Rural2094 (59.0)573 (64.6)553 (62.3)500 (56.4)468 (52.7)Urban1455 (41.0)314 (35.4)334 (37.7)387 (43.6)420 (47.3)Education level, n (%)0.071No formal education1632 (46.0)425 (48.0)418 (47.1)413 (46.6)376 (42.4)Primary school808 (22.8)205 (23.1)210 (23.7)203 (22.9)190 (21.4)Middle or high school707 (19.9)169 (19.1)160 (18.0)176 (19.9)202 (22.8)College or above399 (11.3)87 (9.8)99 (11.2)94 (10.6)119 (13.4)Health, n (%)0.005Poor91 (2.6)14 (1.6)35 (4.0)14 (1.6)28 (3.2)Fair732 (20.6)164 (18.5)173 (19.5)204 (23.0)191 (21.5)Good1886 (53.2)484 (54.5)485 (54.8)465 (52.5)452 (50.9)Very good and above837 (23.6)125 (25.4)192 (21.7)203 (22.9)217 (24.4)Smoking status, n (%) < 0.001Never or former2494 (70.3)570 (64.3)611 (68.9)660 (74.4)653 (73.5)Current1054 (29.7)316 (35.7)276 (31.1)227 (25.6)235 (26.5)Drinking status, n (%) < 0.001Never or former2358 (66.4)515 (58.1)594 (67.0)654 (73.7)595 (67.0)Current1191 (33.6)372 (41.9)293 (33.0)233 (26.3)293 (33.0)Diabetes, n (%)694 (19.6)57 (6.4)90 (10.1)168 (18.9)379 (42.7) < 0.001Dyslipidemia, n (%)1968 (55.5)306 (34.5)425 (47.9)520 (58.6)717 (80.7) < 0.001CHD, n (%)527 (14.9)115 (13.0)117 (13.2)137 (15.5)158 (17.8)0.013Stroke, n (%)96 (2.7)23 (2.6)22 (2.5)14 (1.6)37 (4.2)0.008Chronic diseases, n (%)2777 (78.2)652 (73.5)673 (75.9)717 (80.8)735 (82.8) < 0.001TC, mean ± SD, mg/dL197.26 ± 40.40182.40 ± 34.28192.83 ± 36.55201.34 ± 36.39212.47 ± 47.00 < 0.001TG, mean ± SD, mg/dL149.85 ± 30.7965.34 ± 15.81100.26 ± 17.51143.83 ± 27.60289.80 ± 44.59 < 0.001HDL-C, mean ± SD, mg/dL49.47 ± 15.0859.56 ± 15.2652.43 ± 13.2747.24 ± 11.5638.67 ± 11.63 < 0.001LDL-C, mean ± SD, mg/dL118.34 ± 36.41111.75 ± 30.65122.24 ± 33.77126.49 ± 34.07112.82 ± 43.80 < 0.001FBG, mean ± SD, mg/dL114.62 ± 22.2796.80 ± 16.04103.66 ± 15.84111.19 ± 22.60146.80 ± 28.14 < 0.001HbAlc, mean ± SD, %5.32 ± 0.885.07 ± 0.455.14 ± 0.535.28 ± 0.685.78 ± 1.35 < 0.001Cognitive function score12.17 ± 3.4811.88 ± 3.5311.94 ± 3.5412.41 ± 3.4412.47 ± 3.390.001CESD-10 score in 20115.58 ± 3.575.56 ± 3.555.85 ± 3.585.28 ± 3.505.61 ± 3.630.010CESD-10 score in 20186.28 ± 5.055.17 ± 4.875.68 ± 4.016.60 ± 5.097.65 ± 5.15 < 0.001TyG quartiles: Quartile 1 (< 8.32), Quartile 2 (≥ 8.32–8.73), Quartile 3 (≥ 8.73–9.19), and Quartile 4 (≥ 9.19). BMI: body mass index; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CHD: coronary heart disease; FBG: fasting blood glucose; HbAlc, glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation; TC: total cholesterol; TG: triglycerides; TyG: triglyceride-glucose. Table 1Baseline characteristics of participants categorized by TyG quartiles.CharacteristicOverall (n = 3549)TyGQuartile 1 (n = 887)Quartile 2 (n = 887)Quartile 3 (n = 887)Quartile 4 (n = 888)P valueAge, mean ± SD, years61.1 ± 9.661.7 ± 10.261.7 ± 9.661.5 ± 9.759.5 ± 8.8 < 0.001Gender, n (%) < 0.001Female, n (%)1820 (51.3)367 (41.4)447 (50.4)529 (59.6)477 (53.7)Male, n (%)1729 (48.7)520 (58.6)440 (49.6)358 (40.4)411 (46.3)BMI, kg/m225.05 ± 12.5623.59 ± 11.5825.21 ± 13.7625.44 ± 13.8426.00 ± 14.010.036Married, n (%)3095 (87.2)759 (85.6)768 (86.6)759 (85.6)809 (91.1)0.001Residence, n (%) < 0.001Rural2094 (59.0)573 (64.6)553 (62.3)500 (56.4)468 (52.7)Urban1455 (41.0)314 (35.4)334 (37.7)387 (43.6)420 (47.3)Education level, n (%)0.071No formal education1632 (46.0)425 (48.0)418 (47.1)413 (46.6)376 (42.4)Primary school808 (22.8)205 (23.1)210 (23.7)203 (22.9)190 (21.4)Middle or high school707 (19.9)169 (19.1)160 (18.0)176 (19.9)202 (22.8)College or above399 (11.3)87 (9.8)99 (11.2)94 (10.6)119 (13.4)Health, n (%)0.005Poor91 (2.6)14 (1.6)35 (4.0)14 (1.6)28 (3.2)Fair732 (20.6)164 (18.5)173 (19.5)204 (23.0)191 (21.5)Good1886 (53.2)484 (54.5)485 (54.8)465 (52.5)452 (50.9)Very good and above837 (23.6)125 (25.4)192 (21.7)203 (22.9)217 (24.4)Smoking status, n (%) < 0.001Never or former2494 (70.3)570 (64.3)611 (68.9)660 (74.4)653 (73.5)Current1054 (29.7)316 (35.7)276 (31.1)227 (25.6)235 (26.5)Drinking status, n (%) < 0.001Never or former2358 (66.4)515 (58.1)594 (67.0)654 (73.7)595 (67.0)Current1191 (33.6)372 (41.9)293 (33.0)233 (26.3)293 (33.0)Diabetes, n (%)694 (19.6)57 (6.4)90 (10.1)168 (18.9)379 (42.7) < 0.001Dyslipidemia, n (%)1968 (55.5)306 (34.5)425 (47.9)520 (58.6)717 (80.7) < 0.001CHD, n (%)527 (14.9)115 (13.0)117 (13.2)137 (15.5)158 (17.8)0.013Stroke, n (%)96 (2.7)23 (2.6)22 (2.5)14 (1.6)37 (4.2)0.008Chronic diseases, n (%)2777 (78.2)652 (73.5)673 (75.9)717 (80.8)735 (82.8) < 0.001TC, mean ± SD, mg/dL197.26 ± 40.40182.40 ± 34.28192.83 ± 36.55201.34 ± 36.39212.47 ± 47.00 < 0.001TG, mean ± SD, mg/dL149.85 ± 30.7965.34 ± 15.81100.26 ± 17.51143.83 ± 27.60289.80 ± 44.59 < 0.001HDL-C, mean ± SD, mg/dL49.47 ± 15.0859.56 ± 15.2652.43 ± 13.2747.24 ± 11.5638.67 ± 11.63 < 0.001LDL-C, mean ± SD, mg/dL118.34 ± 36.41111.75 ± 30.65122.24 ± 33.77126.49 ± 34.07112.82 ± 43.80 < 0.001FBG, mean ± SD, mg/dL114.62 ± 22.2796.80 ± 16.04103.66 ± 15.84111.19 ± 22.60146.80 ± 28.14 < 0.001HbAlc, mean ± SD, %5.32 ± 0.885.07 ± 0.455.14 ± 0.535.28 ± 0.685.78 ± 1.35 < 0.001Cognitive function score12.17 ± 3.4811.88 ± 3.5311.94 ± 3.5412.41 ± 3.4412.47 ± 3.390.001CESD-10 score in 20115.58 ± 3.575.56 ± 3.555.85 ± 3.585.28 ± 3.505.61 ± 3.630.010CESD-10 score in 20186.28 ± 5.055.17 ± 4.875.68 ± 4.016.60 ± 5.097.65 ± 5.15 < 0.001TyG quartiles: Quartile 1 (< 8.32), Quartile 2 (≥ 8.32–8.73), Quartile 3 (≥ 8.73–9.19), and Quartile 4 (≥ 9.19). BMI: body mass index; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CHD: coronary heart disease; FBG: fasting blood glucose; HbAlc, glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation; TC: total cholesterol; TG: triglycerides; TyG: triglyceride-glucose. Baseline characteristics of participants categorized by TyG quartiles. TyG quartiles: Quartile 1 (< 8.32), Quartile 2 (≥ 8.32–8.73), Quartile 3 (≥ 8.73–9.19), and Quartile 4 (≥ 9.19). BMI: body mass index; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CHD: coronary heart disease; FBG: fasting blood glucose; HbAlc, glycated hemoglobin; HDL-C: high-density lipoprotein cholesterol; LDL-C: low-density lipoprotein cholesterol; SD: standard deviation; TC: total cholesterol; TG: triglycerides; TyG: triglyceride-glucose. Statistical analysis Data were summarized using descriptive statistics, with results presented as mean ± standard deviation, median (interquartile range), or frequencies and percentages, depending on the type of variable. To analyze categorical variables, the chi-square test was employed, while for continuous variables, either one-way analysis of variance (ANOVA) or the Kruskal–Wallis test was applied, with the latter used for non-normally distributed data. To explore the relationship between the TyG index and depression, logistic regression analyses were performed, with results presented as adjusted odds ratios (OR) and corresponding 95% confidence intervals (CI). Initially, univariate logistic regression (Model 1) was conducted, followed by a multivariate approach in Model 2, which adjusted for age and gender. Model 3 extended these adjustments by including additional potential confounders, such as BMI, marital status, residence, health, educational level, hearing impairment, vision impairment, disability, social isolation, smoking and alcohol status, chronic diseases, diabetes, LDL-C, TC, cognitive function score, and CESD-10 score in 2011. To examine the association between TyG and depression more thoroughly, restricted cubic spline (RCS) analysis was performed. Knots were placed at the 25th, 50th (median), and 75th percentiles of the TyG index distribution, and the TyG variable was analyzed in its original scale without transformation. Additionally, the predictive capacity of the TyG index and its related parameters for depression was evaluated through receiver operating characteristic (ROC) curve analysis, with discriminative performance assessed by calculating the area under the curve (AUC). Cox proportional hazards regression was additionally conducted as a sensitivity analysis to evaluate the robustness of the primary findings. To examine the association between the TyG index and the risk of depression across different subgroups, subgroup analyses were conducted based on age (45–60 years vs. ≥ 60 years), gender (male vs. female), BMI (< 24 kg/m2 vs. ≥ 24 kg/m2), residence (urban vs. rural), and diabetes (yes vs. no). Statistical analyses were performed using R software (version 4.2.2; R Foundation for Statistical Computing, Vienna, Austria), with significance set at a two-tailed P-value of < 0.05. Results Baseline characteristics Table 1 presents the baseline characteristics of the study cohort (n = 3549), with a mean age of 61.1 ± 9.6 years, and 51.3% (n = 1820) female. Participants were categorized into four TyG index quartiles: Q1 (n = 887), Q2 (n = 887), Q3 (n = 887), and Q4 (n = 888). Most participants lived in rural areas (59.0%), with a mean BMI of 25.05 ± 12.56 kg/m2. Additionally, 29.7% of participants were current smokers, and 33.6% reported being current drinkers. Significant differences in several demographic and clinical characteristics were observed across TyG quartiles. Variables including age, marital status, the prevalence of chronic conditions (such as diabetes, dyslipidemia, stroke, and coronary heart disease), lipid profiles (TC, TG, LDL-C, HDL-C), FBG, HbA1c, and cognitive function scores differed significantly among the four groups. Association between TyG and depression The depression assessment during the 2018 follow-up revealed an average score of 6.28 ± 5.05, with 579 participants (16.3%) developing depression. A strong positive association between the TyG index and depression was observed in both crude and fully adjusted models. After adjustment for potential confounders, participants in Q4 had a significantly higher risk of depression compared to those in Q1 (OR: 1.74, 95% CI 1.21–2.51, P < 0.001). However, no statistically significant association was found in the Q2 and Q3 groups (P > 0.05). Continuous analysis demonstrated that each one-unit increase in TyG was associated with a 46% higher risk of depression (OR: 1.46, 95% CI 1.18–1.82, P < 0.001) (Table 2). Additionally, multivariable-adjusted restricted cubic splines confirmed a linear dose–response relationship between the TyG index and depression (overall: P < 0.001; non-linear: P = 0.521, Fig. 2).Table 2The association between TyG index and risk of depression.CategoriesEvent, n (%)Model 1aModel 2bModel 3cOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valuePer 1 unit increase579 (16.3%)1.28 (1.13–1.44) < 0.0011.23 (1.08–1.38)0.0011.46 (1.18–1.82) < 0.001Quartile 1113 (12.7%)RefRefRefQuartile 2137 (15.4%)1.25 (0.96–1.64)0.1021.20 (0.91–1.57)0.1951.14 (0.83–1.58)0.410Quartile 3149 (16.8%)1.38 (1.06–1.80)0.0161.26 (0.96–1.64)0.0961.35 (0.97–1.86)0.072Quartile 4180 (20.3%)1.74 (1.35–2.25) < 0.0011.59 (1.23–2.06) < 0.0011.74 (1.21–2.51) < 0.001P for trend < 0.001 < 0.001 < 0.001TyG: triglyceride-glucose; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CI: confidence interval; OR: odds ratio.aUnadjusted model.bAdjusted for age and gender.cAdjusted for age, gender, body mass index, marital status; residence, educational level, health, hearing impairment, vision impairment, disability, social isolation, smoking status, drinking status, chronic diseases, diabetes, low-density lipoprotein cholesterol, total cholesterol, cognitive function score, and CESD-10 score in 2011.Fig. 2Restricted cubic spline analysis with multivariate-adjusted associations between TyG and depression. CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CI: confidence interval; TyG: triglyceride-glucose. Table 2The association between TyG index and risk of depression.CategoriesEvent, n (%)Model 1aModel 2bModel 3cOR (95% CI)P valueOR (95% CI)P valueOR (95% CI)P valuePer 1 unit increase579 (16.3%)1.28 (1.13–1.44) < 0.0011.23 (1.08–1.38)0.0011.46 (1.18–1.82) < 0.001Quartile 1113 (12.7%)RefRefRefQuartile 2137 (15.4%)1.25 (0.96–1.64)0.1021.20 (0.91–1.57)0.1951.14 (0.83–1.58)0.410Quartile 3149 (16.8%)1.38 (1.06–1.80)0.0161.26 (0.96–1.64)0.0961.35 (0.97–1.86)0.072Quartile 4180 (20.3%)1.74 (1.35–2.25) < 0.0011.59 (1.23–2.06) < 0.0011.74 (1.21–2.51) < 0.001P for trend < 0.001 < 0.001 < 0.001TyG: triglyceride-glucose; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CI: confidence interval; OR: odds ratio.aUnadjusted model.bAdjusted for age and gender.cAdjusted for age, gender, body mass index, marital status; residence, educational level, health, hearing impairment, vision impairment, disability, social isolation, smoking status, drinking status, chronic diseases, diabetes, low-density lipoprotein cholesterol, total cholesterol, cognitive function score, and CESD-10 score in 2011. The association between TyG index and risk of depression. TyG: triglyceride-glucose; CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CI: confidence interval; OR: odds ratio. aUnadjusted model. bAdjusted for age and gender. cAdjusted for age, gender, body mass index, marital status; residence, educational level, health, hearing impairment, vision impairment, disability, social isolation, smoking status, drinking status, chronic diseases, diabetes, low-density lipoprotein cholesterol, total cholesterol, cognitive function score, and CESD-10 score in 2011. Restricted cubic spline analysis with multivariate-adjusted associations between TyG and depression. CESD-10: the 10-item Center for Epidemiologic Studies Depression Scale; CI: confidence interval; TyG: triglyceride-glucose. Predictive performance of TyG, TG, and FBG for depression Figure 3 illustrates the ROC curves for TyG, TG, and FBG in predicting depression. Among these variables, TyG demonstrated the highest AUC of 0.639, outperforming both TG (AUC = 0.589) and FBG (AUC = 0.555).Fig. 3ROC analysis of TyG, TG, and FBG to identify depression. FBG: fasting blood glucose; ROC: receiver operating characteristic; TG: triglycerides; TyG: triglyceride-glucose. ROC analysis of TyG, TG, and FBG to identify depression. FBG: fasting blood glucose; ROC: receiver operating characteristic; TG: triglycerides; TyG: triglyceride-glucose. Subgroup analysis Subgroup analyses, stratified by age, gender, BMI, residence, and diabetes, revealed consistent results, with no significant interactions identified (all P- interaction > 0.05). Within each subgroup, individuals in the highest TyG quartile (Q4) consistently exhibited a significantly higher risk of depression compared to other quartiles (Fig. 4). The association between higher TyG levels and depression risk remained consistent in the sensitivity analysis (Supplementary Table 1).Fig. 4Subgroup analysis between the TyG and depression. BMI: body mass index; CI: confidence intervals; DM: diabetes; OR: odds ratios; TyG: triglyceride-glucose. Subgroup analysis between the TyG and depression. BMI: body mass index; CI: confidence intervals; DM: diabetes; OR: odds ratios; TyG: triglyceride-glucose. Discussion This national longitudinal cohort study of middle-aged and older individuals with hypertension explored the association between the TyG index and the risk of depression. Our results demonstrate a significant positive relationship between elevated TyG levels and an increased likelihood of developing depression, with a clear linear trend observed. Additionally, this association remained consistent across multiple subgroups, including those stratified by age, gender, BMI, residence, and diabetes. These findings suggest that the TyG index may serve as an effective biomarker for stratifying depression risk in hypertensive populations, highlighting the potential benefits of maintaining lower TyG levels in reducing depression risk. Depression is a prevalent psychiatric disorder characterized by persistent low mood, cognitive slowing, and anhedonia, substantially impairing quality of life23,24. According to the World Health Organization, an estimated 322 million people worldwide are affected by depression2. Emerging evidence indicates that depression is strongly associated not only with neurological and metabolic disorders but also with cardiovascular diseases, particularly hypertension. Notably, approximately 26.8% of individuals with hypertension suffer from depression, which may exacerbate difficulties in blood pressure control and elevate the risk of complications5,6,25. These observations highlight the potential clinical significance of addressing depression in the management of hypertensive patients. IR is a well-established feature of hypertension, dyslipidemia, and cardiovascular diseases, and is also closely linked to the development of depression. Studies suggest that IR may elevate the risk of depression by disrupting neurotransmitter balance through mechanisms such as hyperinsulinemia, endothelial dysfunction, and inflammation10–12. However, traditional methods for assessing IR are complex and time-consuming, limiting their clinical utility13. As a simple and cost-effective alternative, the TyG index, derived from TG and FBG, has been widely adopted for evaluating IR14. Evidence indicates that higher TyG levels are not only associated with the progression of cardiovascular diseases and dementia but also with an increased risk of depression. For example, previous studies have shown that elevated TyG levels are significantly linked to a higher risk of depressive symptoms in US adults15,16. Similarly, a positive linear association between TyG levels and depression risk has been observed in Chinese adults, particularly among men, older individuals, and those with obesity17. Moreover, a cross-sectional study of hypertensive populations in the US reported a significant association between higher TyG levels and an increased risk of depression, suggesting that IR may play a role in the pathogenesis of depression in hypertensive patients18. However, longitudinal studies investigating this relationship in middle-aged and older hypertensive populations in China remain limited. Given the potential of the TyG index as a predictor of both cardiovascular and metabolic diseases, this study aimed to assess the association between TyG levels and the risk of depression in Chinese hypertensive patients aged 45 and older, addressing a critical gap in the existing literature and providing insights for the early identification and management of depression in this high-risk population. Our study demonstrated a clear positive association between higher TyG levels and an increased risk of depression among hypertensive patients aged 45 and older, with a linear dose–response relationship. Participants in the highest TyG quartile exhibited a substantially greater risk of developing depression compared to those in the lowest quartile, and this association was consistent across different subgroups stratified by age, gender, BMI, residence, and diabetes status. Notably, our gender-stratified analysis showed that elevated TyG levels were significantly associated with an increased risk of depression in both male and female participants. This suggests that the TyG index may serve as a reliable predictor of depression risk regardless of gender, further supporting its applicability across diverse population groups. Additionally, the TyG index showed superior discriminatory ability for predicting depression compared to other metabolic indicators, suggesting its potential utility as a practical biomarker for depression risk stratification in hypertensive populations. Compared to previous studies, our findings provide longitudinal evidence supporting the association between the TyG index and depression. Earlier cross-sectional studies have demonstrated a positive link between higher TyG levels and depressive symptoms in both American hypertensive patients and the general Chinese population. Unlike prior research, our study extends these findings by confirming this association in a longitudinal context among middle-aged and older hypertensive patients in China. These results underscore the potential of the TyG index as a valuable marker for early identification of depression risk in hypertensive populations, highlighting the importance of managing TyG levels to reduce the burden of depression in this demographic. The association between the TyG index and depression in hypertensive populations may involve multiple mechanisms. First, IR, a common feature of hypertension and atherosclerosis, may contribute to depression risk by causing endothelial dysfunction and reduced cerebral blood flow, particularly playing a critical role in vascular depression. In addition, hypertension has been associated with cerebral small vessel disease and white matter hyperintensities, which represent key neuroanatomical substrates of vascular depression, particularly in older adults26–30. Second, IR can impair insulin transport across the blood–brain barrier, leading to the accumulation of L1 cell adhesion molecule-enriched exosomes, which may disrupt neuroplasticity and promote depressive symptoms31,32. Furthermore, IR is often accompanied by chronic low-grade inflammation, and evidence suggests that the TyG index is positively correlated with pro-inflammatory factors. Such inflammatory responses may exacerbate depression by interfering with neurotransmitter metabolism and neuroendocrine function. Hypertension may also contribute to dysregulation of the hypothalamic–pituitary–adrenal axis and heightened sympathetic nervous system activity, both of which can impair neuroendocrine homeostasis and increase vulnerability to depressive symptoms33–36. Oxidative stress represents another key mechanism; elevated TyG levels can significantly intensify oxidative stress, resulting in the accumulation of free radicals and mitochondrial dysfunction, which ultimately lead to neuronal damage and the onset of depression37–41. Moreover, the TyG index has been shown to predict the progression of atherosclerosis, and both atherosclerosis and endothelial damage may increase depression risk by impairing cerebral blood flow, a mechanism that may be particularly pronounced in hypertensive patients42. The findings of this study suggest that higher TyG levels are significantly associated with an increased risk of depression in hypertensive patients, with this relationship remaining consistent across different subgroups. This indicates that the TyG index could serve as a practical and cost-effective biomarker for early identification of depression risk in this population. Unlike traditional depression screening methods that rely on subjective assessments, the TyG index, derived from routine blood tests, offers an objective and accessible alternative. From a clinical perspective, incorporating TyG index screening into routine evaluations for patients with hypertension, particularly in primary care, cardiology, or endocrinology settings, may facilitate early identification of individuals at increased risk for depression. Such risk stratification could support timely psychological assessment and implementation of targeted behavioral or lifestyle interventions. As the TyG index reflects underlying IR and broader metabolic dysfunction, these findings underscore the value of optimizing metabolic health not only for cardiovascular risk reduction but also for mitigating depression risk. Future studies should examine whether improvements in TyG-related metabolic parameters can reduce depression incidence and explore potential mediating or modifying factors through interventional designs. This study has several limitations. First, as an observational study, the influence of residual or unmeasured confounding factors cannot be completely ruled out despite comprehensive adjustments. Second, although this study employed a longitudinal design, the TyG index was assessed only at baseline, which limited our ability to evaluate its temporal variability and long-term dynamic relationship with depression risk. In addition, some participants were lost to follow-up, and the use of self-reported questionnaires for certain variables may have introduced potential selection and recall bias. Third, the lack of detailed data on antihypertensive medication use may have introduced bias, suggesting that future studies should incorporate such information for more precise insights. Additionally, the study was restricted to middle-aged and older Chinese hypertensive patients, raising concerns about the generalizability of the findings to other populations. Therefore, further large-scale, multicenter longitudinal studies with diverse populations and more comprehensive clinical data are needed to clarify the mechanisms linking TyG levels to depression and to strengthen the evidence for targeted risk management in hypertensive patients. Conclusion In conclusion, this study identified a significant association between higher TyG levels and an increased risk of depression in middle-aged and older hypertensive patients, suggesting that the TyG index may serve as a valuable marker for identifying individuals at elevated risk of depression in this population. Supplementary Information Supplementary Material 1 Supplementary Material 1